Edit
Lee’s Pharmaceuticals
http://www.leespharm.com/en/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 10.12.2025
Active
Listed on the GEM of the Stock Exchange of Hong Kong (“HKEx”) Limited since July 2002 and successfully transferred of listing to the Main Board of the HKEx in May 2010, Lee's Pharmaceutical Holdings Limited (Lee's Pharm or “the Group”) is an integrated research-driven and market oriented biopharmaceutical company publicly listed in Hong Kong with over 25 years’ experience in the pharmaceutical industry in China.
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 4
| Date | Title | Description |
| 10.12.2025 | Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights | Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufac... |
| 01.12.2025 | Lee's Pharm Supports Disaster Relief Efforts for Wang Fuk Court in Tai Po | HONG KONG, Dec. 1, 2025 /PRNewswire/ -- Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court in Tai... |
| 08.11.2024 | Nansha Shines at CIIE: Converging at the Bay, Connecting to the World | SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- This is a news release from Nansha Economic and Technological Development Zone Commerce Bureau, Guangzhou: From November 5 to 10, 2024, the 7th China International Import Expo (CIIE) is being held as s... |
| 12.10.2020 | HK-listed Lee’s Pharmaceutical unit nets $145m co-led by Hillhouse, TPG Asia | Premium Zhaoke Ophthalmology Pharmaceutical (ZKO), an indirect subsidiary of Hong Kong-listed Lee’s Pharmaceutical Holdings Limited, has garnered as much as $145 million in its Series B round co-led by Hillhouse Capital’s Hillhouse COFL and... |